Concepedia
Statistics
Publications
85
Citations
4.9K
H-Index
41
Active since
2001
Affiliations
Texas Tech University(Current)
Texas Tech University Health Sciences Center
St. Jude Children's Research Hospital
Children's Hospital of Philadelphia
Center for Cancer Research
Min H. Kang is an author at Texas Tech University specializing in cancer pharmacology, pharmacology, and oncology.
Publications per year
2001–2022
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Victor Sandor, Susan Bakke, Robert W. Robey et al. · PubMed · 2002 · 510 citations
Medicine, Clinical Pharmacokinetics, Pharmacology +12
Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
John M. Maris, Christopher L. Morton, Richard Görlick et al. · Pediatric Blood & Cancer · 2010 · 232 citations · Full text
Medicine, Oncology, Pharmacology +15
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
John L. Marshall, Naiyer A. Rizvi, John Kauh et al. · Journal of Experimental Therapeutics and Oncology · 2002 · 206 citations
Medicine, Medicinal Chemistry, Pharmacology +13
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Min H. Kang, Yun Hee Kang, Barbara Szymanska et al. · Blood · 2007 · 156 citations · Full text
Medicine, Oncology, Pharmacology +11
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma
Ashujit Tagde, Harpal Singh, Min H. Kang et al. · Blood Cancer Journal · 2014 · 124 citations · Full text
Medicine, Oncology, Pharmacology +13
1–5 of 85